Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

BACKGROUND: For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo, with an acceptable safety profile. However, long-term data on the approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Guttman-Yassky, Emma, Paller, Amy S., Simpson, Eric L., Cork, Michael J., Weisman, Jamie, Browning, John, Soong, Weily, Sun, Xian, Chen, Zhen, Kosloski, Matthew P., Kamal, Mohamed A., Delevry, Dimittri, Chuang, Chien-Chia, O’Malley, John T., Bansal, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142443/
https://www.ncbi.nlm.nih.gov/pubmed/35567671
http://dx.doi.org/10.1007/s40257-022-00683-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142443/
https://www.ncbi.nlm.nih.gov/pubmed/35567671
http://dx.doi.org/10.1007/s40257-022-00683-2

Ejemplares similares